Statement: In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.
Primary_evidence: Adverse Events 1:   Total: 15/31 (48.39%)   Intracardiac Thrombus 1/31 (3.23%)   Diarrhoea 2/31 (6.45%)   Nausea 2/31 (6.45%)   Vomiting 2/31 (6.45%)   Ascites 0/31 (0.00%)   Ileus 1/31 (3.23%)   Small Intestinal Obstruction 1/31 (3.23%)   Multi-Organ Failure 0/31 (0.00%)   Sepsis 1/31 (3.23%)   Weight Decreased 1/31 (3.23%)   Dehydration 2/31 (6.45%)   Hypokalaemia 0/31 (0.00%) Adverse Events 2:   Total: 4/31 (12.90%)   Intracardiac Thrombus 0/31 (0.00%)   Diarrhoea 0/31 (0.00%)   Nausea 0/31 (0.00%)   Vomiting 0/31 (0.00%)   Ascites 1/31 (3.23%)   Ileus 0/31 (0.00%)   Small Intestinal Obstruction 0/31 (0.00%)   Multi-Organ Failure 1/31 (3.23%)   Sepsis 0/31 (0.00%)   Weight Decreased 0/31 (0.00%)   Dehydration 0/31 (0.00%)   Hypokalaemia 1/31 (3.23%)